Oblato Announces That It Has Received a Positive Response from the FDA for the Use of OKN-007 for Patients with High-grade Gliomas in an Expanded Access Program

Oblato, Inc. announced that it has received an agreement from the FDA for its plan to submit an intermediate size expanded access protocol for use of OKN-007 in patients with high-grade gliomas.